BioArctic

BioArctic Net Margin

The Net Profit Margin of BioArctic (BIOA B.ST) as of Sep 26, 2026 is 51.14 %. In the previous year, Net Profit Margin was -68.81 % — a change of -174.32% (higher).

Net Margin

51.14 %

YoY

-174.32%

Last updated:

Net Profit Margin of BioArctic is 2026 51.14 % . Net Profit Margin of BioArctic was 2025 -68.81 % . It decreases by -174.32% higher compared to the previous year.

BioArctic's net margin stands at 51.1%, up from -517.5% several years earlier.

The BioArctic Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
53.45 SEK
Jan 1, 2019
31.40 SEK
Jan 1, 2020
-109.90 SEK
Jan 1, 2021
-517.54 SEK
Jan 1, 2022
-4.90 SEK
Jan 1, 2023
37.22 SEK
Jan 1, 2024
-68.81 SEK
Jan 1, 2025
51.14 SEK
The BioArctic Net Margin history
YEARNet MarginYoY
51.14 %-174.32%
-68.81 %-284.89%
37.22 %-860.07%
-4.90 %-99.05%
-517.54 %+370.93%
-109.90 %-450.02%
31.40 %-41.26%
53.45 %+396.17%
10.77 %-80.24%
54.52 %+510.93%
8.92 %—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Net Profit Margin of BioArctic is 51.14 % in 2026.

Net Profit Margin of BioArctic changed from -68.81 % to 51.14 %, representing a -174.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin BioArctic since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — BioArctic

All Key Metrics — BioArctic